Recent Updates
Recently added Catalysts
QNTM Positive Sentiment Score: 75/100

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis. TORONTO, ON / ACCESSWIRE /

Monday, September 9, 2024 1 min read
Key Takeaway: Quantum Biopharma has signed an agreement with Ingenu CRO to conduct a clinical study focusing on disease progression in patients with primary progressive multiple sclerosis. This collaboration is aimed at facilitating a future phase 2 clinical trial involving Lucid-21-302. The study marks a significant step forward in Quantum Biopharma's research efforts in the field of multiple sclerosis. Dr. Andrzej Chruscinski expressed optimism about the importance of this study for their research program.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agreement signed with Ingenu CRO for a clinical study.
  • Study aims to enhance understanding of disease progression in MS.
  • Advances Quantum Biopharma's multiple sclerosis research program.
  • Preparation for future phase 2 clinical trial with Lucid-MS.

Full Press Release Details

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis.
TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
SOURCE: Quantum Biopharma Ltd.

Frequently Asked Questions

What is the focus of Quantum Biopharma's recent study?

The study focuses on observing disease progression in patients with primary progressive multiple sclerosis.

Who is conducting the clinical study for Quantum Biopharma?

Ingenu CRO Pty Ltd. is conducting the clinical study for Quantum Biopharma.

What is the goal of this clinical study?

The goal is to facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).

When was the agreement with Ingenu CRO signed?

The agreement with Ingenu CRO was signed on August 13, 2024.

Who commented on the importance of the study?

Dr. Andrzej Chruscinski emphasized the study's importance for multiple sclerosis research.

Tags: QNTM Viatris Investor Conferences Healthcare Quantum Biopharma Ingenu CRO clinical trial multiple sclerosis Lucid-21-302
Last updated: Sep 9, 2024